

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6023460

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	WUXI BIOLOGICS (SHANGHAI) CO., LTD.	03/19/2020
RECEIVING PARTY DATA		
Name:	WUXI BIOLOGICS (CAYMAN) INC.	
Street Address:	PO BOX 309, UGLAND HOUSE	
City:	GRAND CAYMAN	
State/Country:	CAYMAN ISLANDS	
Postal Code:	KYL-1104	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	PCT Number:	CN2018106618
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	patent@junhe.com	
Correspondent Name:	JUN HE LAW OFFICES P.C.	
Address Line 1:	2100 GENG ROAD, SUITE 102	
Address Line 4:	PALO ALTO, CALIFORNIA 94303	
ATTORNEY DOCKET NUMBER:	053674-8012US01	
NAME OF SUBMITTER:	JAMES J. ZHU	
SIGNATURE:	/James J. Zhu, Reg. No. 52,396/	
DATE SIGNED:	03/20/2020	
Total Attachments: 2		
source=Assignment_SH_to_KY#page1.tif		
source=Assignment_SH_to_KY#page2.tif		

ASSIGNMENT

THIS ASSIGNMENT is by and between:

- 1) WuXi Biologics (Shanghai) Co., Ltd., a legal entity existing under the laws of People's Republic of China, having an address at 299 Fute Zhong Road, Shanghai 200131, P. R. China (the "**Assignor**"), and
- 2) WuXi Biologics (Cayman) Inc., a legal entity existing under the laws of Cayman Islands, having an address at PO Box 309, Ugland House Grand Cayman, KYI-1104, Cayman Islands (the "**Assignee**").

The Assignor is the owner of any right, title and interest in and to the invention disclosed in the below listed patent applications entitled NOVEL ANTI-CD3EPSILON ANTIBODIES (collectively, "Applications"), identified by:

- a) International Patent Application No. PCT/CN2017/102622 filed on 21/09/2017 (date/month/year); and
- b) International Patent Application No. PCT/CN2018/106618 filed on 20/09/2018 (date/month/year),

and in and to the Applications, and in and to any patents (collectively, "Patents") that may be granted for the Applications.

The Assignor has agreed to assign to the Assignee the Assignor's entire right, title and interest in and to the Applications and the Patents worldwide except for those in People's Republic of China (collectively, "Assigned Applications and Assigned Patents"). People's Republic of China as used herein includes mainland China, Hong Kong, Macau and Taiwan. For avoidance of any doubt, the Assignor retains all rights, title and interest in and to the Applications and Patents in People's Republic of China.


For valuable consideration, the receipt and sufficiency of which Assignor acknowledges, Assignor confirms it sold, assigned, and transferred to Assignee, its

successors, legal representatives and assigns, any and all of rights, title and interest in and to: the Assigned Applications and Assigned Patents; any divisions, continuations, and continuations-in-part of the Assigned Applications, any other application outside People's Republic of China claiming the same priority rights as the Assigned Applications or claiming priority rights outside People's Republic of China from the Assigned Applications; any reissues, reexaminations, or extensions of any and all Assigned Patents; and the right to claim outside People's Republic of China the priority rights deriving from the Assigned Applications (collectively, the "Rights"), whether now existing or hereafter arising. Assignor also agrees to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as Assignee deem necessary or desirable to: perfect Assignee's enjoyment of the Rights; prepare and prosecute the Assigned Applications or any other applications for Assigned Patents; conduct proceedings regarding the Rights, including any litigation or derivation proceedings; or perfect or defend title to the Rights. Assignor requests the Commissioner of Patents to issue any Assigned Patents or any other offices of similar authority to issue any Assigned Patents that may be issued on the Assigned Applications to Assignee.

The Assignor and the Assignee confirm that this assignment was effective from September 18, 2017.

Assignor : WuXi Biologics (Shanghai) Co., Ltd.


Assignee : WuXi Biologics (Cayman) Inc.

Signature: 

Name: Chris Chen

Title: Chief Executive Officer

Date: 03/19/2020

Signature: 

Name: Chris Chen

Title: Chief Executive Officer

Date: 03/19/2020